Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab in Relapsed/Refractory PCNSL or SCNSL
NCT04457869Phase 2Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rulonilimab in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT04457869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457869.